Bristol-Myers Squibb Company Release: One- & Two-Year Survival Rates of 94% And 88% Announced From Phase 1b Trial Of Investigational PD-1 Checkpoint Inhibitor Nivolumab And Yervoy® (ipilimumab) In Advanced Melanoma; Ongoing Phase 2/3 Trials To Confirm Res

Published: Jun 02, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab, an investigational PD-1 immune checkpoint inhibitor, and Yervoy® (ipilimumab) given either concurrently or sequentially in patients with advanced melanoma (n=127). After an additional year of follow up of the cohort that received the concurrent combination regimen of nivolumab 1 mg/kg plus Yervoy 3mg/kg (n=17), the one-year overall survival (OS) rate was 94% and the two-year OS rate was 88%.

Help employers find you! Check out all the jobs and post your resume.

Back to news